Keywords: Astex Pharma, Amuvatinib, Discontinued, Lung cancer, SCLC, Licensing potential

Astex Pharma shares down after company drops amuvatinib development

Article | 25 September 2012

Print This

US drug developer Astex Pharmaceuticals (Nasdaq: ASTX) saw its shares fall 8.1% to $3.05 by close last Friday, after the company revealed ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in